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Abstract
Site-directed mutagenesis was used to characterize the functional role of lysine-411, a conserved amino acid located in putative
transmembrane domain (TMD) 11 of the human reduced folate carrier (hRFC). Lysine-411 was mutagenized to arginine, glutamate, and
leucine, and the mutant constructs (K411R–, K411E–, and K411L–hRFC, respectively) were transfected into hRFC-deficient K562 cells.
The mutant hRFC constructs were all expressed at high levels and restored 22–36% of the methotrexate (MTX) transport level in wild-type
(K43-6) hRFC transfectants. Although 5-formyl tetrahydrofolate (5-CHO-H4PteGlu) uptake levels for both the K411E– and K411L–hRFCs
were also impaired (f 33% and 28%, respectively), a complete restoration of the wild-type level was observed for K411R–hRFC. While
loss of MTX transport activity for the K411R–hRFC transfectant was associated with an incomplete restoration of MTX sensitivity
compared to K43-6 cells, these cells were similarly sensitive to Tomudex. The K411R–hRFC transfectants showed an approximately
threefold decreased growth requirement for 5-CHO-H4PteGlu compared to K43-6 cells. The 5-CHO-H4PteGlu transport stimulation observed
for the wild-type carrier in chloride-free buffer was also observed for K411R–hRFC, however, this response was decreased for the K411E–
and K411L–hRFCs. The preservation of low levels of transport for the K411E– and K411L–hRFCs suggest that the amino acid at position
411 does not directly participate in the binding of anionic hRFC substrates. However, a functionally important role for a basic amino acid at
position 411 was, nonetheless, implied by the increased MTX transport for wild-type hRFC over the K411 mutant hRFCs, and the highly
selective uptake of 5-CHO-H4PteGlu over MTX for K411R–hRFC.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Membrane transport of methotrexate (MTX) and related
agents into tumor cells is key to chemotherapeutic effective-
ness since the level of drug achieved within cells is an
important determinant of the extent of binding to intra-
cellular enzyme targets [1]. Membrane transport is also
critical to the metabolism of antifolates to polyglutamyl
forms required for drug retention and, for certain analogs
(Lometrexol, Tomudex), high affinity binding to intracellu-
lar enzymes [1–3]. Thus, it is not surprising that impaired
membrane transport is a common mode of antifolate drug
resistance [1–3].
Decreased drug uptake generally involves alterations in
the reduced folate carrier (RFC). For MTX, impaired RFC
function has been reported in cultured murine and human
tumor cells [4–12], and in murine tumor cells derived in
vivo during MTX chemotherapy [13]. In addition, a wide
range of RFC expression was described in lymphoblasts
from patients with acute lymphoblastic leukemia (ALL)
[14,15] and low levels of RFC were detected at relapse
[14], suggesting an important role for RFC in clinical
resistance. For osteosarcomas, decreased RFC expression
was associated with a poor response to chemotherapy
including MTX [16].
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The characterization of the molecular alterations in RFC
accompanying resistance has begun to shed light on partic-
ular amino acid residues or domains that are essential for
transport substrate binding and/or membrane translocation.
Thus, conserved amino acids located in the human RFC
(hRFC) transmembrane domain (TMD) 1 (glycine-44 [10],
glutamate-45 [12], serine-46 [11] and isoleucine-48 [17]),
TMD 4 (serine-127 [10] and alanine-132 [18]), and TMD 8
(serine-313 [6]) have all been implicated as important to
carrier function based on their capacities to confer resistance
to antifolates. From the predicted membrane topology and
homology comparisons between hRFC and the rodent
carriers, potentially important charged amino acids in the
TMDs have been identified. For instance, our recent studies
suggested important structural roles for aspartate-88 (located
in TMD 2) and arginine-133 (in TMD 4) in the maintenance
of optimal hRFC function, via their participation in a
charge-pair association [19]. By scanning leucine muta-
genesis of the murine RFC (mRFC), important roles for
arginine-131 (homologous to arginine-133 in hRFC) and
arginine-366 (hRFC arginine-373) were likewise suggested
[20].
Interestingly, replacement of lysine-404 (lysine-411 in
hRFC) by leucine in mRFC resulted no appreciable change
in MTX transport or kinetics [20]. However, K404L–mRFC
exhibited a unique transport phenotype, including strikingly
decreased binding affinities and transport for reduced
folates [e.g., 5-formyl tetrahydrofolate (5-CHO-H4PteGlu)]
and a loss of the well documented inhibitory effect of
chloride ion on RFC function [20]. In this report, we extend
these results to hRFC and the homologous lysine-411. In
contrast to the results with the murine carrier, we found that
replacement of lysine-411 with leucine resulted in a sig-
nificant and essentially comparable loss of transport activity
with both MTX and 5-CHO-H4PteGlu. While similar results
were obtained upon substitution of glutamate for lysine-411
in hRFC, replacement with arginine restored a unique
pattern of transport activity that was remarkably selective
for 5-CHO-H4PteGlu over MTX.
2. Materials and methods
2.1. Reagents
[3V,5V,7-3H] (20 Ci/mmol) and [3V,5V,7,9-3H] (17 Ci/mmol)
(6S) 5-CHO-H4PteGlu were purchased from Moravek Bio-
chemicals. Unlabeled MTX and (6R,S) 5-CHO-H4PteGlu
(leucovorin) were provided by the Drug Development
Branch, National Cancer Institute, Bethesda, MD. Both
labeled and unlabeled MTX were purified by HPLC prior
to use [21]. Tomudex was provided by AstraZeneca Phar-
maceuticals. Restriction and modifying enzymes were
obtained from Promega (Madison, WI) or Roche (Indian-
apolis, IN). Synthetic oligonucleotides were obtained from
Invitrogen. Tissue culture reagents and supplies were pur-
chased from assorted vendors with the exception of dialyzed
fetal bovine serum (Life Technologies) and iron-supple-
mented calf serum (Hyclone Laboratories, Inc.).
2.2. Cell culture
The transport-deficient K500E subline was selected from
wild-type K562 cells, as previously described [9]. Cells
were maintained in RPMI 1640 medium, 10% iron-supple-
mented calf serum, 2 mM L-glutamine, 100 U/ml penicillin,
and 100 Ag/ml streptomycin, in a humidified atmosphere at
37 jC in the presence of 5% CO2. Cells were routinely
grown in media containing 0.5 AM MTX; however, prior to
transport assays (see below), MTX was removed from the
medium. The K43-6 subline was derived from K500E cells
by transfection with full-length wild-type hRFC cDNA in
pCDNA3 [9]. K43-6 cells were grown in the presence of 1
mg/ml G418.
For cytotoxicity determinations, cells were cultured in
24-well culture dishes at f 50,000 cells/ml in 2 ml of
complete RPMI 1640 containing 10% dialyzed fetal bovine
serum. Cells were counted with a hemacytometer after 96 h.
The IC50 values were calculated as the concentrations of
MTX necessary to inhibit growth by 50% compared to
control cells grown under identical conditions except that
the growth inhibitor was omitted. For assays of leucovorin
growth requirements, cells were first cultured in complete
folate-free RPMI 1640 media including dialyzed serum,
plus 60 AM adenosine and 10 AM thymidine, for 2 weeks.
The cells were then cultured in 24-well dishes in folate-free
medium without nucleosides, supplemented with a range of
nanomolar concentrations of leucovorin. Cell growth was
measured as for the cytotoxicity assays and the concentra-
tions of leucovorin capable of supporting 50% maximal
growth were calculated.
2.3. Mutagenesis and stable transfections
Mutant hRFC constructs were prepared by PCR as pre-
viously described [19], using the complementary mutagene-
sis primers in Table 1. For all the K411 mutants, two separate
amplicons were initially amplified, using the forward muta-
tion primer and RFCout12 (5Vgacaaccccttccccctgcactctgt3V;
positions 1647 to 1619), and KS2 (5Vcgcagcctcttcttcaaccgc3V;
positions 622 to 642) with the reverse mutation primer. PCR
conditions for the primary PCRs were 94 jC for 30 s, 56 jC
for 45 s, and 72 jC for 60 s. Secondary PCRs were performed
with the KS2/RFCout12 primers and primary PCR products
as templates, using the same conditions as for the primary
PCRs. The secondary PCR products were digested with NotI
and SfiI, purified, and ligated into NotI- and SfiI-digested
hRFC cDNA in pCDNA3 (designated pC43) for transforma-
tion. All mutant hRFC constructs were confirmed by auto-
mated sequencing.
The mutant hRFC cDNAs were transfected into trans-
port-impaired K500E cells with lipofectin [9]. Cells were
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cloned in 0.35% Noble agar in complete medium and clones
resistant to G418 (1 mg/ml) were isolated and expanded for
further analysis [9].
2.4. Western blot analysis of mutant hRFC-transfectants
Plasma membranes were prepared by differential centri-
fugation [22]. Membrane proteins were electrophoresed on
7.5% polyacrylamide gels in the presence of SDS [23], and
electroblotted onto polyvinylidene fluoride (PVDF) mem-
branes (Pierce) [24]. The blots were developed with protein
A-purified hRFC-specific antibody [10] and enhanced
chemiluminescence (Roche), and exposed to X-ray film
with multiple exposures. Densitometry was performed on
a Kodak Digital Science Image Station 440CF.
2.5. Transport assay of mutant hRFC constructs
Initial rates of [3H]-MTX (0.5 AM) or [3H]-(6S)5-CHO-
H4PteGlu (1 AM) uptake were measured over 180 s as
previously described [9,10,19,22]. Levels of intracellular
radioactivity were expressed as pmol/mg protein, calculated
from direct measurements of radioactivity and protein con-
tents of the cell homogenates. Protein assays were by the
method of Lowry et al. [25]. Kinetic constants (Kt, Vmax)
were calculated from Lineweaver–Burk plots for 3H-MTX
and 3H-5-CHO-H4PteGlu, and Ki values for Tomudex were
determined from Dixon plots, with 3H-MTX as the transport
substrate. For the studies designed to assess the inhibitory
effects of chloride on 3H-5-CHO-H4PteGlu uptake, trans-
port assays were performed at 0.5 AM substrate in Hepes-
buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl,
2 mM MgCl2, and 5 mM glucose, pH 7.4) and an anion-free
Hepes-sucrose buffer (20 mM Hepes, 235 mM sucrose, pH
adjusted to 7.4 with MgO).
3. Results and discussion
Analysis of membrane topology models and sequence
homologies between the rodent and human RFCs permits
the identification of functionally important amino acids. Of
particular interest are the conserved basic amino acids
located in the predicted TMDs of hRFC, including argi-
Fig. 1. Topology structure of the human reduced folate carrier. A topology model for hRFC (‘‘TMPRED’’ [26]) is shown depicting 12 putative TMDs,
internally oriented amino and carboxyl termini, and an externally oriented N-glycosylation site at asparagine 58. Conserved residues between the rodent and
human RFCs are shown in black. The locations of the conserved arginines 133 and 373, and lysine-411 (as striped circles) are also noted. The numbers (1–12)
in the lower bar designate the number of putative TMDs. The predicted membrane topology of TMDs 1–8 and the carboxyl terminus of hRFC has been
experimentally verified [27,28].
Table 1
PCR primers for preparing hRFC mutant constructs
Mutations Forward mutation primer Reverse mutation primer
K411R 5VC TTTGCCACCATCGTCAGGAC CATCATCACT TTC 3V 5VGAAAGTGATGATGGTCCTGACGATGGTGGCAAAG 3V
K411L 5VC TTTGCCACCATCGTCCTGAC CATCATCACT TTC 3V 5VGAAAGTGATGATGGTCAGGACGATGGTGGCAAAG 3V
K411E 5VC TTTGCCACCATCGTCGAGAC CATCATCACT TTC 3V 5VGAAAGTGATGATGGTCTCGACGATGGTGGCAAAG 3V
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nine-133 and -373, and lysine-411 (Fig. 1). Transport
activity for mRFC with MTX and reduced folates was
abolished upon replacement of the homologous arginine-
131 and arginine-363 residues with leucines [20]. Likewise,
for lysine-404 in mRFC, corresponding to lysine-411 in
hRFC, leucine substitution resulted in a loss in binding
affinity and transport of reduced folates. However, transport
of MTX by the K404L–mRFC carrier was essentially
unchanged from wild-type levels [20].
3.1. Transport properties of mutant K411–hRFCs
The novelty of the K404L mRFC phenotype led us to
further explore the possible role of this highly conserved
cationic amino acid in the maintenance of hRFC structure
and transport function. Accordingly, we systematically
mutagenized lysine-411 in hRFC to arginine, glutamate,
and leucine, and transfected the mutant hRFC constructs
(designated K411R–, K411E–, and K411L–hRFC, respec-
tively) into MTX resistant K562 (i.e., K500E) cells, char-
acterized by a 7.7-fold increased dihydrofolate reductase
content and nearly undetectable levels of hRFC transcripts
and protein [9]. G418-resistant clones were isolated, expan-
ded, and plasma membrane proteins prepared, for analyses
of hRFC expression on Western blots with hRFC-specific
antibody [10]. A Western blot for representative clonal
isolates expressing the K411–hRFC mutant proteins is
shown in Fig. 2A, for comparison with K43-6 cells,
expressing high levels of wild-type hRFC (f 20-fold over
the levels in K562 parent cells; 9). Only slight differences in
levels of carrier expression between wild-type and mutant
hRFC transfectants were observed, suggesting that amino
Fig. 2. Immunoblot analysis and transport activity of wild type and mutant hRFCs expressed in K500E cells. Panel A: Data are shown for a western blot of
plasma membrane proteins from hRFC-null K500E cells and transfectants expressing wild type hRFC (K43-6) and mutant hRFCs including K411R– ,
K411E– , and K411L–hRFC (the latter are labeled R, E, and L, respectively). Proteins (20 Ag) were fractionated on a 7.5% gel in the presence of SDS and
electroblotted onto a PVDF membrane. Detection was with anti-hRFC antibody and an enhanced chemiluminescence kit (Roche). Molecular weight standards
(in kDa) are shown. The relative levels of hRFC protein by densitometry are noted. Panels B–E: Data are shown for the relative uptakes of 3H-MTX and 3H-5-
CHO-H4PteGlu (abbreviated LCV) over 180 s at 37 jC. In panels B and C, are shown the absolute uptake rates in pmol/mg cell protein (mean values from 3–4
experimentsF S.E.). In panels D and E, are shown the normalized transport data, using the relative hRFC expression levels from the western blot.
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acid substitutions at position 411 have no major adverse
effects on hRFC expression or membrane targeting.
Transfectants expressing the mutant and wild-type
hRFCs were assayed for cellular uptake with 3H-MTX
and 3H-5-CHO-H4PteGlu (Fig. 2B–E). All K411 substitu-
tions restored only low levels of 3H-MTX transport, ranging
fromf 22% of wild type for the K411E–hRFC transfectant
to 36% for the K411L–hRFC transfectant. These values
were slightly changed (to 14% and 63%, respectively) when
transport was normalized for modest differences in hRFC
expression (Fig. 2D). These effects of the K411 substitu-
tions on MTX uptake were reflected in both the MTX Kt
(f 2–3-fold increase) and Vmax values (50–60% decrease)
(Table 2).
Somewhat different results were obtained with 3H-(6S)5-
CHO-H4PteGlu as the transport substrate. Thus, signifi-
cantly impaired 3H-5-CHO-H4PteGlu uptake was observed
for both the K411E– and K411L–hRFCs (f 33% and
28%, respectively), and a complete restoration of wild-type
3H-5-CHO-H4PteGlu uptake was observed for K411R–
hRFC (Fig. 2C). When adjusted for the slight differences
in hRFC protein, these uptake values changed to 21% for
K411E–hRFC and 50% for K411L–hRFC, and to 135% of
wild-type levels for K411R–hRFC (panel E). Elevated 3H-
5-CHO-H4PteGlu uptake for K411R–hRFC was associated
with threefold decreased Kt and Vmax values, compared to
K43-6 cells (Table 2). For the K411E– and K411L–hRFCs,
Kt values were essentially unchanged from the wild-type
value accompanying a three- to sixfold decreased Vmax
values.
These results suggest a somewhat modified spectrum of
transport properties for K411L–hRFC compared to the
homologous K404L–mRFC. Whereas the K404L–mRFC
selectively retained high level MTX transport over 5-CHO-
H4PteGlu, for the corresponding hRFC mutant, a significant
and similar loss of transport occurred with both substrates.
Although the charge properties at position 411 appear to
have only a slight effect on carrier function for MTX, for 5-
CHO-H4PteGlu, transport was clearly fostered by the pres-
ence of a positively charged residue at this position. The
dramatic stimulation of 5-CHO-H4PteGlu transport over
MTX by K411R–hRFC in large part reflects f 3-fold
increased binding affinity for the reduced folate and f 3-
fold decreased binding affinity for the antifolate substrate
compared to the wild-type carrier.
3.2. K411R–hRFC confers a selective pattern of antifolate
resistance and decreased growth requirements for leucovorin
The loss of MTX transport activity in cells expressing
K411R–hRFC was associated with an incomplete restora-
tion of MTX sensitivity compared to the K43-6 cells (IC50’s
of 90 and 38 nM, respectively, versus 880 nM for K500E
cells; Fig. 3A). Interestingly, the transfectant expressing
K411R–hRFC showed an increased affinity for the anti-
folate Tomudex (Ki = 0.940F 21 AM) over K43-6 cells
(Ki = 7.03F 2.14 AM). This was reflected in the complete
restoration of high level Tomudex sensitivity for the
K411R–hRFC transfectant in outgrowth assays (IC50’s of
4.2 versus 6.1 nM for K43-6 cells and 31 nM for K500E
cells) (Fig. 3B). The decreased Kt of K411R–hRFC for 5-
CHO-H4PteGlu (Table 2) was accompanied by a decreased
growth requirement for leucovorin [(6R,S)5-CHO-H4Pte-
Glu] for the K411R–hRFC transfectant (f 3-fold lower
than that for K43-6 cells and 19-fold lower than for K500E
cells; Fig. 3C).
3.3. Chloride dependence for the mutant K411–hRFC
transporter
A characteristic feature of RFC involves an inhibition of
transport by chloride ions and marked stimulation in anion-
free buffers [20,29,30]. For K404L–mRFC, only 10% of
the maximum level of stimulation in wild-type cells was
found when transport assays were performed in Hepes–
sucrose anion-free buffer [20]. For wild-type hRFC in K43-
6 cells, uptake of 3H-5-CHO-H4PteGlu was, likewise,
stimulated (3.1-fold) in anion-free Hepes–sucrose buffer
over Hepes-buffered saline (20 mM HEPES, 140 mM NaCl,
5 mM KCl, 2 mM MgCl2, and 5 mM glucose, pH 7.4). For
Table 2
Kinetic constants for MTX and CHO-H4PteGlu transport by hRFC wild-type and mutant K411–hRFCs




K43-6 MTX 1.80F 0.50 33.59F 6.01 18.66 33.59 18.60
K411R–hRFC MTX 5.02F 0.79 21.77F 2.29 4.34 34.02 6.78
K411E–hRFC MTX 5.80F 0.86 14.39F 2.9 2.48 8.99 1.55
K11L–hRFC MTX 3.42F 1.03 16.12F 4.10 4.71 28.28 8.26
K43-6 5-CHO-H4PteGlu 2.28F 0.51 29.51F 4.32 12.94 29.51 12.94
K411R–hRFC 5-CHO-H4PteGlu 0.75F 0.16 11.56F 1.66 15.41 18.06 24.07
K411E–hRFC 5-CHO-H4PteGlu 1.84F 0.48 7.29F 1.05 3.96 4.56 2.47
K411L–hRFC 5-CHO-H4PteGlu 1.31F 0.08 4.98F 1.31 3.80 8.74 6.66
Kinetic constants for MTX and 5-CHO-H4PteGlu were determined from Lineweaver Burk plots for the transfectants expressing the wild-type lysine-411 (K43-
6) and the mutant K411R– , K411E– and K411L–hRFC constructs, as described in the text. The normalized Vmax and Vmax/Kt values are also shown,
normalized for the hRFC expression level on Western blots (i.e., Fig. 2A). The data shown are mean values from three to five independent experiments with
standard errors of the mean.
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the mutant hRFCs, the extent of stimulation was variable,
and ranged from 3.2-fold for K411R–hRFC, to 2.2-fold for
K411E–hRFC and 1.9-fold for K411L–hRFC. While these
results suggest that the maintenance of a positive charge at
position 411 is not absolutely required for chloride inhib-
ition of transport, nonetheless, a positively charge amino
acid at the position is essential to achieving a maximum
inhibitory response by excess chloride ion.
4. Conclusion
The earlier finding of a significantly preferred substrate
activity for MTX over reduced folates for the K404L–
mRFC was not observed with the homologous K411L–
hRFC construct. This implies that the structural or func-
tional role of this residue differs between the mouse and
human transporters. For hRFC, lysine-411 does not likely
directly participate in the binding of anionic substrates,
since low level transport was independent of charge at this
position for K411L–, K411E–, and K411R–hRFCs with
MTX, and for K411L– and K411E–hRFCs with 5-CHO-
H4PteGlu. However, an indirect involvement of a basic
amino acid at position 411 in substrate binding was, none-
theless, implied by our finding that substitution of arginine
for lysine-411 in K411R–hRFC substantially increased 5-
CHO-H4PteGlu binding while similarly decreasing the bind-
ing of MTX. Thus, MTX and 5-CHO-H4PteGlu must bind
somewhat differently to hRFC. The continued character-
ization of essential structural and functional features of
hRFC should facilitate the design of new, more potent
antifolate chemotherapeutic agents, based on their capacities
Fig. 3. Cytotoxicity of MTX and Tomudex; growth requirements for Leucovorin [(6R,S)5-CHO-H4PteGlu). In panels A and B are shown the MTX and
Tomudex cytotoxicity curves for parental K562, K43-6, and K500E cells, for comparison with the K411R–hRFC transfectants. Results are presented as the
percent cell outgrowth at each drug concentration relative to cells cultured in the absence of drug. IC50 values for MTX were: parental K562, 6.8 nM; K43-6
cells, 38 nM; K411R–hRFC transfectant, 90 nM; K500E cells, 880 nM. For Tomudex, the IC50 values were: parental K562, 3.6 nM; K411R–hRFC
transfectant, 4.2 nM; K43-6 cells, 6.1 nM; K500E cells, 31 nM. In panel C are shown the growth curves for the cell lines cultured in folate-free medium with
dialyzed fetal bovine serum, supplemented with low nanomolar concentrations of leucovorin. Results are presented as the percent growth at various low
concentrations of leucovorin relative to the level in the presence of 100 nM leucovorin. The 50% growth response values for leucovorin are as follows: parental
K562, 4.2 nM; K43-6 cells, 1.9 nM; K411R–hRFC transfectant, 0.68 nM; K500E cells 13 nM.
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for membrane transport. If hRFC mutants with significantly
increased specificities for reduced folate over antifolate
substrates can be identified, these may be useful tools for
gene therapy applications in combination with antifolates.
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